Merck & Co. Announces Promising Results from Ifinatamab Deruxtecan Phase 2 Trial for Small Cell Lung Cancer
Merck & Co. Inc. announced promising results from the IDeate-Lung01 Phase 2 trial for ifinatamab deruxtecan (I-DXd) in treating extensive-stage small cell lung cancer (ES-SCLC). The trial showed a 48.2% objective response rate in previously treated patients. Discussions with global regulatory authorities are ongoing to evaluate the drug's potential benefits for patients who have undergone prior treatments, including platinum-based chemotherapy. The results were presented at the 2025 World Conference on Lung Cancer.
Merck & Co. Inc. announced results from the IDeate-Lung01 Phase 2 trial, which demonstrated that ifinatamab deruxtecan (I-DXd) exhibited clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). The trial results were presented at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. The study reported an objective response rate of 48.2% among patients treated with ifinatamab deruxtecan. Ongoing discussions with global regulatory authorities are underway to further assess the potential benefits of this antibody drug conjugate for patients who have undergone previous treatments, including platinum-based chemotherapy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief on September 07, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
